Fenglin Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fenglin Jiang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Qiuya Yang
Department of Emergency, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
2 shared publicationsWen Jie
Department of Emergency, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
2 shared publicationsYan Liu
Hospital Infection Management Department, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
2 shared publicationsYing Wang
Department of Emergency, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
2 shared publications- Bhushan Sandeep
Department of Cardio-Thoracic Surgery, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People’s Hospital, Chengdu Second People’s Hospital, Chengdu
1 shared publication - Dan Xiong
Department of Cardio-Thoracic Surgery, Chengdu Second People's Hospital, Chengdu, Sichuan, 610017, China
1 shared publication
Latest Publications
- 18 July 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (10) , 103398
Observational analyses in cardiovascular device evaluation, methods, applications, and challenges: A comprehensive review
- 18 July 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (10) , 103398
Observational analyses in cardiovascular device evaluation, methods, applications, and challenges: A comprehensive review
- Open Access
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1861119
Comparison of ultrasound-guided quadratus lumborum block and other regional blocks for postoperative pain in cesarean section: a systematic review and meta-analysis of randomized clinical trials
Background: Acute post-cesarean section (C/S) pain causes adverse maternal outcomes, and multimodal opioid-sparing analgesia is central to Enhanced Recovery after Surgery (ERAS) protocols. Quadratus lumborum block (QLB) is a promising regional technique, but evidence comparing it with other regional blocks remains fragmented. Methods: We conducted a systematic review and meta-analysis of RCTs (PubMed, EMBASE, Web of Science; inception to September 2025). Eligible studies included adults undergoing C/S with QLB. Primary outcome was 24-h cumulative morphine consumption; secondary outcomes included pain scores, recovery metrics, and adverse events. RoB 2 and GRADE assessed study quality and evidence certainty. Results: Twenty-three RCTs (1,935 patients) were included. QLB reduced 24-h (MD = −3.19; 95% CI, −5.09, −1.30; p = 0.0009) and 48-h (MD = −16.51; 95%CI, −27.64, −5.39; p = 0.004) morphine consumption, and 24-h dynamic pain scores (MD = −0.52; 95% CI, −0.87, −0.17; p = 0.003). No significant differences were observed in resting pain, recovery metrics, satisfaction, or opioid-related adverse events. GRADE certainty for the primary outcome was moderate. Conclusion: QLB was associated with modest reductions in postoperative opioid consumption and 24-h dynamic pain after C/S; however, the clinical significance is limited (pain reduction below the minimally clinically important difference), and the certainty of evidence is moderate-to-low due to very high heterogeneity (I 2 > 90%). QLB may be considered as one component of multimodal analgesia in selected patients, particularly those without intrathecal morphine co-administration. No additional benefits on resting pain, recovery metrics, satisfaction, or adverse events were identified. Systematic review registration: https://doi.org/10.37766/inplasy2026.6.0029 , identifier: INPLASY202660029.
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1861119
Open AccessComparison of ultrasound-guided quadratus lumborum block and other regional blocks for postoperative pain in cesarean section: a systematic review and meta-analysis of randomized clinical trials
Background: Acute post-cesarean section (C/S) pain causes adverse maternal outcomes, and multimodal opioid-sparing analgesia is central to Enhanced Recovery after Surgery (ERAS) protocols. Quadratus lumborum block (QLB) is a promising regional technique, but evidence comparing it with other regional blocks remains fragmented. Methods: We conducted a systematic review and meta-analysis of RCTs (PubMed, EMBASE, Web of Science; inception to September 2025). Eligible studies included adults undergoing C/S with QLB. Primary outcome was 24-h cumulative morphine consumption; secondary outcomes included pain scores, recovery metrics, and adverse events. RoB 2 and GRADE assessed study quality and evidence certainty. Results: Twenty-three RCTs (1,935 patients) were included. QLB reduced 24-h (MD = −3.19; 95% CI, −5.09, −1.30; p = 0.0009) and 48-h (MD = −16.51; 95%CI, −27.64, −5.39; p = 0.004) morphine consumption, and 24-h dynamic pain scores (MD = −0.52; 95% CI, −0.87, −0.17; p = 0.003). No significant differences were observed in resting pain, recovery metrics, satisfaction, or opioid-related adverse events. GRADE certainty for the primary outcome was moderate. Conclusion: QLB was associated with modest reductions in postoperative opioid consumption and 24-h dynamic pain after C/S; however, the clinical significance is limited (pain reduction below the minimally clinically important difference), and the certainty of evidence is moderate-to-low due to very high heterogeneity (I 2 > 90%). QLB may be considered as one component of multimodal analgesia in selected patients, particularly those without intrathecal morphine co-administration. No additional benefits on resting pain, recovery metrics, satisfaction, or adverse events were identified. Systematic review registration: https://doi.org/10.37766/inplasy2026.6.0029 , identifier: INPLASY202660029.
- Open Access
- 16 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1737121
Perioperative dexmedetomidine and renal outcomes in adult cardiac surgery: an updated systematic review and meta-analysis
Background: Acute kidney injury (AKI) is a common complication following cardiac surgery, associated with increased morbidity and mortality. Dexmedetomidine (DEX), a highly selective α-2 adrenoceptor agonist, has shown potential renal protective effects, but evidence remains inconsistent. This study aims to evaluate the efficacy of DEX in preventing AKI and improving renal outcomes in cardiac surgery patients through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: A comprehensive search of PubMed, Cochrane Library, Embase, and Web of Science was conducted until April 2025. PICOS criteria were applied to select studies comparing DEX with placebo/normal saline in cardiac surgery patients. Primary outcomes included AKI incidence; secondary outcomes encompassed intraoperative parameters, postoperative recovery, and complications. Results: Bibliometric analysis highlighted China and the USA as leading contributors, with emerging trends in pediatric and mechanistic research. Among 16 RCTs ( n = 2,882), DEX significantly reduced AKI incidence [RR 0.58; 95% CI 0.37 to 0.91; I 2 = 74%, p = 0.02], particularly at 0.6–0.1 μg/kg/h doses [RR 0.43; 95% CI 0.26 to 0.71; I 2 = 0%, p = 0.001]. Subgroup analysis revealed 0.4 μg/kg/h doses failed to yield a statistically significant benefit [RR 0.65; 95% CI 0.36 to 1.17; I 2 = 84%; p = 0.15]. DEX also shortened ICU stay [MD −1.23; 95% CI −2.17 to −0.30; I 2 = 93%; p = 0.01], mechanical ventilation duration [MD −1.24; 95% CI −2.15 to −0.33; I 2 = 97%; p = 0.008], and hospital stays [MD −0.33; 95% CI −0.54 to −0.13; I 2 = 86%; p = 0.01]. However, it did not affect mortality or intraoperative times. Conclusion: DEX demonstrates significant renal protection and improves postoperative recovery in cardiac surgery patients, though optimal dosing requires further investigation. These findings support its integration into perioperative protocols but underscore the need for standardized dosing regimens. Systematic review registration: Identifier, INPLASY2025120019.
- 16 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1737121
Open AccessPerioperative dexmedetomidine and renal outcomes in adult cardiac surgery: an updated systematic review and meta-analysis
Background: Acute kidney injury (AKI) is a common complication following cardiac surgery, associated with increased morbidity and mortality. Dexmedetomidine (DEX), a highly selective α-2 adrenoceptor agonist, has shown potential renal protective effects, but evidence remains inconsistent. This study aims to evaluate the efficacy of DEX in preventing AKI and improving renal outcomes in cardiac surgery patients through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: A comprehensive search of PubMed, Cochrane Library, Embase, and Web of Science was conducted until April 2025. PICOS criteria were applied to select studies comparing DEX with placebo/normal saline in cardiac surgery patients. Primary outcomes included AKI incidence; secondary outcomes encompassed intraoperative parameters, postoperative recovery, and complications. Results: Bibliometric analysis highlighted China and the USA as leading contributors, with emerging trends in pediatric and mechanistic research. Among 16 RCTs ( n = 2,882), DEX significantly reduced AKI incidence [RR 0.58; 95% CI 0.37 to 0.91; I 2 = 74%, p = 0.02], particularly at 0.6–0.1 μg/kg/h doses [RR 0.43; 95% CI 0.26 to 0.71; I 2 = 0%, p = 0.001]. Subgroup analysis revealed 0.4 μg/kg/h doses failed to yield a statistically significant benefit [RR 0.65; 95% CI 0.36 to 1.17; I 2 = 84%; p = 0.15]. DEX also shortened ICU stay [MD −1.23; 95% CI −2.17 to −0.30; I 2 = 93%; p = 0.01], mechanical ventilation duration [MD −1.24; 95% CI −2.15 to −0.33; I 2 = 97%; p = 0.008], and hospital stays [MD −0.33; 95% CI −0.54 to −0.13; I 2 = 86%; p = 0.01]. However, it did not affect mortality or intraoperative times. Conclusion: DEX demonstrates significant renal protection and improves postoperative recovery in cardiac surgery patients, though optimal dosing requires further investigation. These findings support its integration into perioperative protocols but underscore the need for standardized dosing regimens. Systematic review registration: Identifier, INPLASY2025120019.
- Open Access
- 12 December 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1702898
Analgesic efficacy of erector spinae plane block for managing pain in arthroscopic shoulder surgery: a systemic review and meta-analysis
Background: Whether the erector spinae plane block (ESPB) truly relieves pain after arthroscopic shoulder surgery (ASS) is still unsettled. We therefore examined whether ESPB sharpens post-operative pain control in these patients. Methods: We systematically searched the Cochrane Library, PubMed, Embase, and Web of Science for randomized controlled trials (RCTs) comparing ESPB with any comparator (no block, sham block, or alternative regional block) in patients undergoing ASS. The primary outcome was cumulative opioid consumption within the first 24 h postoperatively. Secondary outcomes included pain scores at rest and during movement, incidence of postoperative nausea and vomiting (PONV), time to first rescue analgesic request, and patient-reported satisfaction with analgesia. Results: Six RCTs comprised of 365 patients met inclusion criteria. ESPB did not reduce 24-h opioid consumption versus control (SMD −1.11; 95% CI −2.55 to 0.33; p = 0.13, I 2 = 96%). Pain scores were lower with ESPB at 2 h (SMD −0.83; 95% CI −1.30 to −0.37; p = 0.0005, I 2 = 35%) and 48 h (SMD −0.64; 95% CI −1.08 to −0.20; p = 0.004, I 2 = 95%), but not at 4 h. Furthermore, time to first rescue analgesic was prolonged by ESPB (SMD 4.04; 95% CI 0.77–7.31; p = 0.02, I 2 = 99%). However, ESPB did not reduce the rest and movement pain scores at 2 h (SMD −0.87; 95% CI −2.98 to 1.24; p = 0.42; I 2 = 97%; SMD −0.98; 95% CI −3.00 to 1.04; p = 0.34; I 2 = 97%) and 4 h (SMD −0.43; 95% CI −2.31 to 1.46; p = 0.66; I 2 = 97%; SMD −0.89; 95% CI −2.57 to 0.80; p = 0.30; I 2 = 96%), respectively. PONV and other adverse events were comparable. Subgroup analysis of single-injection ESPB also showed no opioid-sparing effect (SMD −1.46; 95% CI −3.21 to 0.30; p = 0.10, I 2 = 97%). Patient-reported satisfaction revealed no significant difference between ESPB and control group. Conclusion: The ESPB fails to reduce 24-h opioid consumption, pain scores at rest and movement at early stage, and the incidence of PONV. Nevertheless, it prolonged the time to first rescue analgesic without elevating the risk of adverse events. Systematic review registration: PROSPERO, registration number CRD 42023395027, https://www.crd.york.ac.uk/PROSPERO/view/CRD42023395027 .
- 12 December 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1702898
Open AccessAnalgesic efficacy of erector spinae plane block for managing pain in arthroscopic shoulder surgery: a systemic review and meta-analysis
Background: Whether the erector spinae plane block (ESPB) truly relieves pain after arthroscopic shoulder surgery (ASS) is still unsettled. We therefore examined whether ESPB sharpens post-operative pain control in these patients. Methods: We systematically searched the Cochrane Library, PubMed, Embase, and Web of Science for randomized controlled trials (RCTs) comparing ESPB with any comparator (no block, sham block, or alternative regional block) in patients undergoing ASS. The primary outcome was cumulative opioid consumption within the first 24 h postoperatively. Secondary outcomes included pain scores at rest and during movement, incidence of postoperative nausea and vomiting (PONV), time to first rescue analgesic request, and patient-reported satisfaction with analgesia. Results: Six RCTs comprised of 365 patients met inclusion criteria. ESPB did not reduce 24-h opioid consumption versus control (SMD −1.11; 95% CI −2.55 to 0.33; p = 0.13, I 2 = 96%). Pain scores were lower with ESPB at 2 h (SMD −0.83; 95% CI −1.30 to −0.37; p = 0.0005, I 2 = 35%) and 48 h (SMD −0.64; 95% CI −1.08 to −0.20; p = 0.004, I 2 = 95%), but not at 4 h. Furthermore, time to first rescue analgesic was prolonged by ESPB (SMD 4.04; 95% CI 0.77–7.31; p = 0.02, I 2 = 99%). However, ESPB did not reduce the rest and movement pain scores at 2 h (SMD −0.87; 95% CI −2.98 to 1.24; p = 0.42; I 2 = 97%; SMD −0.98; 95% CI −3.00 to 1.04; p = 0.34; I 2 = 97%) and 4 h (SMD −0.43; 95% CI −2.31 to 1.46; p = 0.66; I 2 = 97%; SMD −0.89; 95% CI −2.57 to 0.80; p = 0.30; I 2 = 96%), respectively. PONV and other adverse events were comparable. Subgroup analysis of single-injection ESPB also showed no opioid-sparing effect (SMD −1.46; 95% CI −3.21 to 0.30; p = 0.10, I 2 = 97%). Patient-reported satisfaction revealed no significant difference between ESPB and control group. Conclusion: The ESPB fails to reduce 24-h opioid consumption, pain scores at rest and movement at early stage, and the incidence of PONV. Nevertheless, it prolonged the time to first rescue analgesic without elevating the risk of adverse events. Systematic review registration: PROSPERO, registration number CRD 42023395027, https://www.crd.york.ac.uk/PROSPERO/view/CRD42023395027 .
- Open Access
- 2 September 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1630657
Analgesic efficacy of ultrasound-guided ESPB on metabolic surgery
Background: This systematic review and meta-analysis assessed the analgesic efficacy of ultrasound-guided ESPB in metabolic surgery.Methods: A systematic literature search of PubMed, the Cochrane Library, Web of Science, and Embase was conducted from database inception to February 2025 to identify randomized controlled trials (RCTs) comparing ultrasound-guided erector spinae plane block (ESPB) with either no block, sham block, or alternative regional analgesic techniques in patients undergoing metabolic surgery. Primary outcomes included 24 h postoperative opioid consumption, while secondary outcomes encompassed pain scores, time to first analgesic requirement, postoperative nausea and vomiting, and patient satisfaction. Risk of bias was assessed using the Cochrane Risk of Bias Tool, and evidence quality was evaluated using GRADE.Results: Ten RCTs involving 729 patients were included. ESPB significantly reduced 24 h opioid consumption [mean difference (MD): −6.68; 95% CI: −10.75, −2.61; p = 0.001] and resting pain scores at 24 h [MD: −0.78; 95% CI: −1.10, −0.46; p < 0.00001]. Movement pain scores were also reduced to 6, 12, 24, and 48 h (p < 0.00001 for all). ESPB prolonged the time to first rescue analgesic [MD: 14.17; 95% CI: 5.50, 22.85; p = 0.001]. However, no significant differences were observed in PONV incidence or patient satisfaction scores.Conclusion: Ultrasound-guided ESPB is an effective and safe analgesic technique for metabolic surgery, significantly reducing opioid consumption and pain scores while delaying the need for rescue analgesics.Systematic review registration: PROSPERO 2025 CRD420251000358. Available from https://www.crd.york.ac.uk/PROSPERO/view/CRD420251000358.
- 2 September 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1630657
Open AccessAnalgesic efficacy of ultrasound-guided ESPB on metabolic surgery
Background: This systematic review and meta-analysis assessed the analgesic efficacy of ultrasound-guided ESPB in metabolic surgery.Methods: A systematic literature search of PubMed, the Cochrane Library, Web of Science, and Embase was conducted from database inception to February 2025 to identify randomized controlled trials (RCTs) comparing ultrasound-guided erector spinae plane block (ESPB) with either no block, sham block, or alternative regional analgesic techniques in patients undergoing metabolic surgery. Primary outcomes included 24 h postoperative opioid consumption, while secondary outcomes encompassed pain scores, time to first analgesic requirement, postoperative nausea and vomiting, and patient satisfaction. Risk of bias was assessed using the Cochrane Risk of Bias Tool, and evidence quality was evaluated using GRADE.Results: Ten RCTs involving 729 patients were included. ESPB significantly reduced 24 h opioid consumption [mean difference (MD): −6.68; 95% CI: −10.75, −2.61; p = 0.001] and resting pain scores at 24 h [MD: −0.78; 95% CI: −1.10, −0.46; p < 0.00001]. Movement pain scores were also reduced to 6, 12, 24, and 48 h (p < 0.00001 for all). ESPB prolonged the time to first rescue analgesic [MD: 14.17; 95% CI: 5.50, 22.85; p = 0.001]. However, no significant differences were observed in PONV incidence or patient satisfaction scores.Conclusion: Ultrasound-guided ESPB is an effective and safe analgesic technique for metabolic surgery, significantly reducing opioid consumption and pain scores while delaying the need for rescue analgesics.Systematic review registration: PROSPERO 2025 CRD420251000358. Available from https://www.crd.york.ac.uk/PROSPERO/view/CRD420251000358.